These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1654459)

  • 1. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals.
    Lai CF; Gong SC; Esteban M
    J Virol; 1991 Oct; 65(10):5631-5. PubMed ID: 1654459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional properties of the 14-kDa envelope protein of vaccinia virus synthesized in Escherichia coli.
    Lai CF; Gong SC; Esteban M
    J Biol Chem; 1990 Dec; 265(36):22174-80. PubMed ID: 2266120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans.
    Demkowicz WE; Maa JS; Esteban M
    J Virol; 1992 Jan; 66(1):386-98. PubMed ID: 1727494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 32-kilodalton envelope protein of vaccinia virus synthesized in Escherichia coli binds with specificity to cell surfaces.
    Lai CF; Gong SC; Esteban M
    J Virol; 1991 Jan; 65(1):499-504. PubMed ID: 1985213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
    Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
    Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural analysis and immunogenicity of recombinant major envelope protein (rA27L) of buffalopox virus, a zoonotic Indian vaccinia-like virus.
    Kumar A; Yogisharadhya R; Bhanuprakash V; Venkatesan G; Shivachandra SB
    Vaccine; 2015 Oct; 33(41):5396-5405. PubMed ID: 26319070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
    J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning of the vaccinia virus ribonucleotide reductase small subunit gene. Characterization of the gene product expressed in Escherichia coli.
    Howell ML; Sanders-Loehr J; Loehr TM; Roseman NA; Mathews CK; Slabaugh MB
    J Biol Chem; 1992 Jan; 267(3):1705-11. PubMed ID: 1309792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of TGEV spike protein gp195 expressed in E. coli and by a TGE-vaccinia virus recombinant.
    Hu S; Bruszewski J; Smalling R; Browne JK
    Adv Exp Med Biol; 1985; 185():63-82. PubMed ID: 3000150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice.
    Hall RA; Brand TN; Lobigs M; Sangster MY; Howard MJ; Mackenzie JS
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1287-94. PubMed ID: 8683218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant.
    Ludvíková V; Kunke D; Hamsíková E; Kutinová L; Vonka V
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1445-9. PubMed ID: 1646285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.
    Vázquez MI; Esteban M
    J Virol; 1999 Nov; 73(11):9098-109. PubMed ID: 10516016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge.
    Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G
    J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus.
    Hu SL; Zarling JM; Chinn J; Travis BM; Moran PA; Sias J; Kuller L; Morton WR; Heidecker G; Benveniste RE
    Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7213-7. PubMed ID: 2550935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
    Shinoda K; Wyatt LS; Irvine KR; Moss B
    Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against refolded recombinant envelope protein (domain III) of Japanese encephalitis virus inhibit the JEV infection to Porcine Stable Kidney cells.
    Verma SK; Gupta N; Pattnaik P; Babu JP; Rao PV; Kumar S
    Protein Pept Lett; 2009; 16(11):1334-41. PubMed ID: 20001924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.